This is a governance restructuring with no financial data — neutral for the stock. Monitor DUBLIN-4 enrollment updates and the upcoming 8-K amendment for CEO/CFO compensation terms. The forfeiture of Huang's unvested equity removes a potential overhang but is not a catalyst.
Price Chart
Executive Summary
BeyondSpring announced a leadership transition effective July 1, 2026: founder/CEO Dr. Lan Huang steps down as CEO (remains Chairman) to focus on SEED Therapeutics; Min Qiu appointed CEO and Na Li appointed CFO, both with a mandate to execute the confirmatory DUBLIN-4 Phase 3 trial for Plinabulin. The filing includes no financial data, guidance, or material operational updates — it is a governance restructuring with no quantifiable impact on fundamentals.
Key Facts
- Founder/CEO Dr. Lan Huang transitions from CEO to Chairman effective July 1, 2026; all her unvested equity and long-term incentive awards forfeited.
- Min Qiu appointed CEO effective July 1, 2026; employment terms not yet finalized.
- Na Li appointed CFO effective July 1, 2026; employment terms not yet finalized.
- Dr. Jiangwen Majeti appointed Vice Chairman of the Board; receives one-time grant of options to purchase 100,000 shares vesting over 4 years.
- DUBLIN-4 is a 442-patient confirmatory Phase 3 trial of Plinabulin plus docetaxel in non-squamous EGFR wild-type NSCLC post-ICI.
- No financial results, guidance, or preliminary data disclosed in this filing.
Financial Impact
No financial figures disclosed. Leadership transition is a governance event with no immediate revenue, earnings, or cash flow impact.
Risk Factors
- CEO/CFO compensation terms not yet disclosed — could include dilutive equity grants.
- DUBLIN-4 execution risk remains the primary binary catalyst; no update on enrollment or timeline in this filing.
- Founder CEO departure may signal reduced strategic focus on BeyondSpring vs. SEED Therapeutics.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003908 |
| Document: f8k_060426.htm | 0001171843-26-003908 |
| Document: 0001171843-26-003908-index-headers.html | 0001171843-26-003908 |
| Document: 0001171843-26-003908-index.html | 0001171843-26-003908 |
| Document: 0001171843-26-003908.txt | 0001171843-26-003908 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4620 (−28.37%) |
Oct 2, 2026 25d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4620 (+41.22%) |
Sep 29, 2026 28d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4620 (−40.26%) |
Sep 29, 2026 28d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4620 (+40.26%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4620 (+37.57%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4620 (−25.25%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4620 (−35.07%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4620 (−35.07%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4620 (−72.98%) |
Jun 2, 2026 21w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4620 (−72.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers